OncoLink

Thank you so much for publishing an article on OncoLink [F. Hoke, The Scientist, April 3, 1995, page 1]. I thought it was a good, balanced report. I believe that a quality future for OncoLink, or OncoLink by another name, will happen only if discussion concerning OncoLink has a good media forum. Thank you for providing such a forum. I don't believe that the present editors of OncoLink understand the dynamics necessary to keep OncoLink current and responsive to patients' needs. They envisioned

Written byLinda Yarger
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

I believe that a quality future for OncoLink, or OncoLink by another name, will happen only if discussion concerning OncoLink has a good media forum. Thank you for providing such a forum.

I don't believe that the present editors of OncoLink understand the dynamics necessary to keep OncoLink current and responsive to patients' needs. They envisioned themselves primarily as editors or reviewers. Essentially this is a passive role. OncoLink attained its former status because Loren Buhle did not operate in a passive role. By reading Internet Usenet and mailing/discussion lists and by participating in the CompuServe cancer forum, he stayed informed about patients' most urgent concerns. A concept of what material is needed and the dedication to find such material is part of what Buhle provided. In addition, he provided that information in a timely manner.

In my opinion, OncoLink is currently becoming stale. As time goes, I am guessing ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies